RU2008146518A - Биомаркеры инфекции, вызываемой вирусом гепатита с - Google Patents
Биомаркеры инфекции, вызываемой вирусом гепатита с Download PDFInfo
- Publication number
- RU2008146518A RU2008146518A RU2008146518/13A RU2008146518A RU2008146518A RU 2008146518 A RU2008146518 A RU 2008146518A RU 2008146518/13 A RU2008146518/13 A RU 2008146518/13A RU 2008146518 A RU2008146518 A RU 2008146518A RU 2008146518 A RU2008146518 A RU 2008146518A
- Authority
- RU
- Russia
- Prior art keywords
- genes
- individual
- expression
- infection
- characteristic set
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 5
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 12
- 241000700605 Viruses Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79552006P | 2006-04-26 | 2006-04-26 | |
| US60/795,520 | 2006-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008146518A true RU2008146518A (ru) | 2010-06-10 |
Family
ID=38656353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008146518/13A RU2008146518A (ru) | 2006-04-26 | 2007-04-25 | Биомаркеры инфекции, вызываемой вирусом гепатита с |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100028874A1 (enExample) |
| EP (1) | EP2016195A4 (enExample) |
| JP (1) | JP2009535036A (enExample) |
| KR (1) | KR20090023360A (enExample) |
| CN (1) | CN101479389A (enExample) |
| AU (1) | AU2007244824A1 (enExample) |
| CA (1) | CA2650616A1 (enExample) |
| IL (1) | IL194920A0 (enExample) |
| MX (1) | MX2008013796A (enExample) |
| NO (1) | NO20084954L (enExample) |
| NZ (1) | NZ573052A (enExample) |
| RU (1) | RU2008146518A (enExample) |
| WO (1) | WO2007127801A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| JP2009178057A (ja) * | 2008-01-29 | 2009-08-13 | Miyazakiken Sangyo Shien Zaidan | インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット |
| CA2738477A1 (en) * | 2008-09-24 | 2010-04-01 | Robert S. Kauffman | Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis |
| EP2561363B1 (en) | 2010-04-21 | 2021-07-14 | Memed Diagnostics, Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| CN102178927A (zh) * | 2011-03-01 | 2011-09-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途 |
| CN102323426A (zh) * | 2011-08-08 | 2012-01-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 用于诊断或筛查丙型肝炎病毒感染的试剂 |
| CN108802385B (zh) | 2012-02-09 | 2022-02-08 | 米密德诊断学有限公司 | 用于诊断感染的标记和决定因素和其使用方法 |
| EP3129036B1 (en) * | 2014-04-11 | 2021-08-11 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| CA3190715A1 (en) | 2014-08-14 | 2016-02-18 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| WO2016026258A1 (en) * | 2014-08-22 | 2016-02-25 | Institute Of Biophysics, Chinese Academy Of Sciences | Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins |
| WO2016059636A1 (en) | 2014-10-14 | 2016-04-21 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| WO2016092554A1 (en) | 2014-12-11 | 2016-06-16 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| EP3423589B1 (en) | 2016-03-03 | 2021-07-21 | Memed Diagnostics Ltd. | Analyzing rna for diagnosing infection type |
| US11466331B2 (en) | 2016-03-03 | 2022-10-11 | Memed Diagnostics Ltd. | RNA determinants for distinguishing between bacterial and viral infections |
| CA3022616A1 (en) | 2016-06-07 | 2017-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosis of bacterial and viral infections |
| WO2018011796A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| CN109661578B (zh) | 2016-07-10 | 2022-05-10 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的蛋白质特征 |
| EP3519834A4 (en) | 2016-09-29 | 2020-06-17 | MeMed Diagnostics Ltd. | RISK ASSESSMENT AND DISEASE CLASSIFICATION METHODS |
| EP3519833B1 (en) | 2016-09-29 | 2024-08-14 | MeMed Diagnostics Ltd. | Methods of prognosis and treatment |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| CN108379584B (zh) * | 2018-04-12 | 2020-08-11 | 上海交复生物医药科技有限公司 | RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性 |
| CN110448548B (zh) * | 2018-05-08 | 2023-05-05 | 四川大学华西医院 | Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途 |
| KR102289533B1 (ko) * | 2019-08-19 | 2021-08-17 | 주식회사 테라젠바이오 | 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램 |
| CN111333710B (zh) * | 2020-03-04 | 2021-12-03 | 暨南大学 | C20orf24蛋白缺失突变体及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004073599A2 (en) * | 2003-02-18 | 2004-09-02 | Pfizer Inc. | Inhibitors of hepatitis c virus, compositions and treatments using the same |
| US20050282179A1 (en) * | 2003-12-05 | 2005-12-22 | Applera Corporation | Biomarkers for interferon-alpha response in hepatitis C virus infected patients |
| AU2005321808B2 (en) * | 2004-12-30 | 2009-08-20 | University Of Louisville Research Foundation, Inc. | Genetic markers of schizophrenia |
-
2007
- 2007-04-25 KR KR1020087028981A patent/KR20090023360A/ko not_active Ceased
- 2007-04-25 CN CNA200780023526XA patent/CN101479389A/zh active Pending
- 2007-04-25 JP JP2009507945A patent/JP2009535036A/ja active Pending
- 2007-04-25 MX MX2008013796A patent/MX2008013796A/es not_active Application Discontinuation
- 2007-04-25 CA CA002650616A patent/CA2650616A1/en not_active Abandoned
- 2007-04-25 US US12/298,353 patent/US20100028874A1/en not_active Abandoned
- 2007-04-25 NZ NZ573052A patent/NZ573052A/en not_active IP Right Cessation
- 2007-04-25 AU AU2007244824A patent/AU2007244824A1/en not_active Abandoned
- 2007-04-25 RU RU2008146518/13A patent/RU2008146518A/ru not_active Application Discontinuation
- 2007-04-25 WO PCT/US2007/067421 patent/WO2007127801A2/en not_active Ceased
- 2007-04-25 EP EP07761284A patent/EP2016195A4/en not_active Withdrawn
-
2008
- 2008-10-26 IL IL194920A patent/IL194920A0/en unknown
- 2008-11-25 NO NO20084954A patent/NO20084954L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007127801A2 (en) | 2007-11-08 |
| AU2007244824A1 (en) | 2007-11-08 |
| EP2016195A4 (en) | 2010-03-10 |
| IL194920A0 (en) | 2009-08-03 |
| MX2008013796A (es) | 2009-03-31 |
| CA2650616A1 (en) | 2007-11-08 |
| US20100028874A1 (en) | 2010-02-04 |
| CN101479389A (zh) | 2009-07-08 |
| NZ573052A (en) | 2012-03-30 |
| WO2007127801A3 (en) | 2008-09-12 |
| NO20084954L (no) | 2009-01-22 |
| KR20090023360A (ko) | 2009-03-04 |
| JP2009535036A (ja) | 2009-10-01 |
| EP2016195A2 (en) | 2009-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008146518A (ru) | Биомаркеры инфекции, вызываемой вирусом гепатита с | |
| Zhang et al. | The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies | |
| Hartman et al. | Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein | |
| Liu et al. | Transcriptome analysis of genes responding to NNV infection in Asian seabass epithelial cells | |
| Duggal et al. | Evidence for co-evolution of West Nile Virus and house sparrows in North America | |
| JP2014519487A5 (enExample) | ||
| Mao et al. | Virologic and immunologic characteristics in mature ducks with acute duck hepatitis A virus 1 infection | |
| Borges et al. | Trapping the enemy: Vermamoeba vermiformis circumvents Faustovirus mariensis dissemination by enclosing viral progeny inside cysts | |
| McCarthy et al. | Head start immunity: characterizing the early protection of C strain vaccine against subsequent classical swine fever virus infection | |
| Choi et al. | Expression profiles of host immune response‐related genes against HEV genotype 3 and genotype 1 infections in rhesus macaques | |
| Torres‐Puente et al. | Genetic variability in hepatitis C virus and its role in antiviral treatment response | |
| He et al. | Human viruses: An ever-increasing list | |
| Teimouri et al. | Single-nucleotide polymorphisms in host pattern-recognition receptors show association with antiviral responses against SARS-CoV-2, in-silico trial | |
| Younossi et al. | Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon‐alfa and ribavirin | |
| Álvarez-Torres et al. | Molecular characterization and expression analyses of the Solea senegalensis interferon-stimulated gene 15 (isg15) following NNV infections | |
| Dos Santos et al. | Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection | |
| Rasmussen et al. | Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques | |
| Plauzolles et al. | Influence of host resistance on viral adaptation: hepatitis C virus as a case study | |
| Kumthip et al. | Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG‐IFN and RBV therapy | |
| Yağci et al. | Molecular identification of adenoviral conjunctivitis in Turkey | |
| Burt et al. | Crimean-Congo Hemorrhagic Fever Virus, an Emerging and Re-emerging Pathogen of Public Health Concern | |
| Prasetyo et al. | Molecular status of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among transgender commercial sex workers in Surakarta, Indonesia | |
| Jain et al. | Hepatitis G virus (HGV) infection & its pathogenic significance in patients of cirrhosis | |
| Idowu et al. | The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency | |
| Shafat et al. | Identification of Stage-Specific Differentially Expressed Genes and Network Meta-Analysis Reveals Potential Molecular Signatures in Chronic Hepatitis E Virus Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130319 |